Latest / This Week In Medicine
NEJM January 22,2026:Nivolumab for Resected Stage III or IV Melanoma at 9 Years
This long-term clinical study evaluates the effectiveness of two different immunotherapy drugs in preventing the return of advanced melanoma following surgical removal. By tracking patients over a nine-year period, researchers demonstrated that nivolumab provides a more durable defense against cancer recurrence compared to ipilimumab. While both treatments showed similar results regarding total lifespan, patients receiving nivolumab experienced fewer distant metastases and required less follow-up systemic therapy. Ultimately, these final findings confirm that nivolumab remains a superior and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.